ArticleBiochemistry and biophysics reports2026
LNP-mediated silencing of oncogenic lncRNA PVT1 enhances chemotherapeutic efficacy in osteosarcoma.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is an aggressive bone malignancy characterized by early metastasis, chemoresistance, and poor prognosis, particularly in recurrent or metastatic cases. The long non-coding RNA PVT1 has been implicated as an oncogene in various cancers, but its therapeutic potential in osteosarcoma remains underexplored. This study investigates the feasibility of targeting PVT1 using lipid nanoparticle-encapsulated siRNA (LNP-siPVT1) as a standalone or combination therapy for osteosarcoma. PVT1 expression was found to be significantly upregulated in osteosarcoma cell lines (U2OS, Saos-2, MG-63), patient tissues, and public datasets (GSE126209 and GSE309091). Tumor-targeted LNPs encapsulating siPVT1 were synthesized via microfluidic mixing and exhibited a mean diameter of ∼100 nm, favorable encapsulation efficiency, and accelerated siRNA release under acidic pH (5.5). In vitro, LNP-siPVT1 effectively suppressed PVT1 expression, reduced cell viability (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.